Ernexa Therapeutics (NASDAQ:ERNA) Announces Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) issued its quarterly earnings data on Friday. The company reported ($1.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.84) by $1.95, Zacks reports.

Ernexa Therapeutics Price Performance

Shares of ERNA traded up $0.04 during mid-day trading on Friday, hitting $1.87. The stock had a trading volume of 7,904 shares, compared to its average volume of 63,210. Ernexa Therapeutics has a 52 week low of $1.74 and a 52 week high of $46.11. The business has a fifty day moving average price of $3.01 and a 200-day moving average price of $6.91. The firm has a market cap of $3.05 million, a P/E ratio of -0.13 and a beta of 2.75.

Wall Street Analyst Weigh In

A number of research firms recently commented on ERNA. Wall Street Zen lowered Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.